Add to a list

Inactive Instrument

Cell Source, Inc. Stock Other OTC

CLCS

US15114L1044

Biotechnology & Medical Research

OTC Markets Traded

Latest news : Cell Source, Inc.

15/05	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
07/04	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
07/04	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/11/24	Cell Source, Inc. Shared Positive Interim Results from Its Phase 1/2 First-In-Human Clinical Trial Conducted At the University of Texas Md Anderson Cancer Center	CI
15/11/24	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
20/08/24	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
30/07/24	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/06/24	Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24/06/24	Cell Source, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/03/24	Cell Source, Inc. announced that it has received $4.76017 million in funding	CI
10/11/23	Cell Source, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
20/09/23	Cell Source, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
24/08/23	Cell Source, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

More news

Press Releases: Cell Source, Inc.

21/05	Cell Source Presented Its Breakthrough Developments for Mismatched Donor Stem Cell and Organ Transplants and Off-the-shelf CAR-T Cell Therapy at the LD Micro Invitational Conference in Los Angeles This Week	AQ
15/05	Cell Source, Inc. to Present at the LD Micro Invitational XVI	NE
15/05	Cell Source : Quarterly Report for Quarter Ending March 31, 2025 (Form 10-Q)	PU
07/04	Cell Source : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
09/12/22	Note 2 - Going Concern and Management Plans	AQ

More press releases

Managers and Directors: Cell Source, Inc.

Manager	Title	Age	Since
Itamar Shimrat CEO	Chief Executive Officer	66	30/06/2014

Director	Title	Age	Since
Dennis Brown CHM	Chairman	77	18/05/2015
Darlene Soave BRD	Director/Board Member	82	25/03/2021
George Verstraete BRD	Director/Board Member	72	10/03/2022

More insiders

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	24.41M 21.34M 19.61M 18.28M 34.67M 2.32B 35.2M 235M 91.52M 1.14B 91.63M 89.66M 3.94B	P/E 2023	-2.65x	P/E 2024	-2.49x
Enterprise Value	34.92M 30.53M 28.05M 26.15M 49.6M 3.32B 50.35M 337M 131M 1.63B 131M 128M 5.63B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	80.32%	Yield 2023 *	-	Yield 2024	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELL SOURCE, INC.	-.--%	+2.22%	-	-	63.19M
ARGENX SE	+0.68%	+5.92%	+80.45%	+137.78%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.51%	+94.88%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+45.58%	-1.42%	19.69B
GENMAB A/S	-0.29%	+9.78%	+44.62%	-27.94%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+178.93%	+360.74%	16.22B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+42.82%	-	14.84B
Average	+2.58%	+8.57%	+54.64%	+148.04%	27.28B
Weighted average by Cap.	+2.46%	+6.47%	+59.06%	+137.71%

	2023	2024
Net sales	-	-
Net income	-5.32M -4.65M -4.28M -3.98M -7.56M -507M -7.67M -51.32M -19.95M -249M -19.97M -19.54M -858M	-4.51M -3.94M -3.63M -3.38M -6.41M -430M -6.51M -43.52M -16.92M -211M -16.94M -16.57M -728M
Net Debt	9.27M 8.11M 7.45M 6.94M 13.17M 883M 13.37M 89.45M 34.77M 434M 34.81M 34.06M 1.5B	10.51M 9.19M 8.44M 7.87M 14.93M 1B 15.15M 101M 39.4M 492M 39.44M 38.6M 1.69B

Cell Source, Inc. Stock Other OTC

Stocks

CLCS

US15114L1044

Biotechnology & Medical Research

Valuation: Cell Source, Inc.

Latest news : Cell Source, Inc.

Press Releases: Cell Source, Inc.

Managers and Directors: Cell Source, Inc.

Bio Therapeutic Drugs

Financials

Company Profile